Premium
Variation of the epidermal expression of glucocorticoid receptor‐beta as potential predictive marker of bullous pemphigoid outcome
Author(s) -
Brulefert Adrien,
Le Jan Sébastien,
Plée Julie,
Durlach Anne,
Bernard Philippe,
Antonicelli Frank,
TrussardiRégnier Aurélie
Publication year - 2017
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13444
Subject(s) - glucocorticoid , medicine , glucocorticoid receptor , immunohistochemistry , predictive marker , bullous pemphigoid , epidermis (zoology) , biopsy , disease , skin biopsy , endocrinology , oncology , pathology , immunology , antibody , cancer , anatomy
Abstract Bullous pemphigoid ( BP ) is the most common autoimmune subepidermal blistering disease in Western countries. Although topical and/or systemic glucocorticoids treatment efficacy is widely recognized, up to 30% of patients with BP may undergo a relapse during the first year of treatment. We investigated the protein expression of the total glucocorticoid receptor and GR β isoform in the skin biopsy specimens from patients with BP and wondered whether such investigation at baseline provided a tool to predict disease outcome. Total GR and GR β protein expressions were detected by immunohistochemistry at baseline on 12 patients who later relapse and 11 patients who remained on remission in comparison with 14 control patients. The expression of GR β in the epidermis of patients with BP who later relapse was significantly higher than that in the epidermis of patients with BP controlled upon corticosteroid treatment, which was also higher than control patients. Thus, our results suggest that increased protein expression of GR β in skin epithelial cells is predictive of reduced steroid treatment efficacy, and therefore of increased risk of disease relapse in patients with BP .